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Abstract
Background Response shift theory suggests that
improvements in health lead patients to change their
internal standards and re-assess former health states as
worse than initially rated when using retrospective ratings
via the then-test. The predictions of response shift theory
can be illustrated using prospect theory, whereby a change
in current health causes a change in reference frame.
Therefore, if health deteriorates, the former health state
will receive a better rating, whereas if it improves, the
former health state will receive a worse rating.
Objective To explore the predictions of response shift
and prospect theory by relating subjective change to
objective change.
Methods Baseline and 3-month follow-up data from a
cohort of rheumatoid arthritis patients (N = 197) starting
on TNFa-blocking agents were used. Objective disease
change was classiﬁed according to a disease-speciﬁc clin-
ical outcome measure (DAS28). Visual analogue scales
(VAS) for general health (GH) and pain were used as self-
reported measures. Three months after starting on anti-
TNFa, patients used the then-test to re-rate their baseline
health with regard to general health and pain. Differences
between then-test value and baseline values were calcu-
lated and tested between improved, non-improved and
deteriorated patients by the Student t-test.
Results At 3 months, 51 (25.9%) patients had good
improvement in health, 83 (42.1%) had moderate improve-
ment,and63(32.0%)hadnoimprovementordeterioratedin
health.Allpatientsnomatterwhethertheyimproved,didnot
improve, or even became worse rated their health as worse
retrospectively. The difference between the then-test rating
and the baseline value was similarly sized in all groups.
Conclusion More positive ratings of retrospective health
are independent of disease change. This suggests that
patients do not necessarily change their standards in line
with their disease change, and therefore it is inappropriate
to use the then-test to correct for such a change. If a then-
test is used to correct for shifts in internal standards, it
might lead to the paradoxical result that patients who do
not improve or even deteriorate increase signiﬁcantly on
self-reported health and pain. An alternative explanation
for differences in retrospective and prospective ratings of
health is the implicit theory of change which is more
successful in explaining our results than prospect theory.
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Introduction
When a physician sees a patient, the most frequently asked
question will probably be ‘‘How do you feel today con-
cerning your general health (or pain)?’’. This question can
be formally measured using a Visual Analogue Scale
(VAS) for general health (GH) or pain, which is considered
a feasible, valid and reliable method [1–3]. In the ﬁeld of
rheumatology, indices based on patient reported outcomes,
among which the VAS GH and VAS pain, are suggested to
use for systematically monitoring patients on therapy
effectiveness [4]. In general, to compare assessments over
time and between individuals, it is a prerequisite of a
measurement that the patient’s concept of the subject of
assessment is the same in all situations. However, there are
many examples of patients reporting their health state as
stable over time, despite improvements in their objective
health status [5–12], which challenge the use of self-
reporting outcomes. It has been shown in a variety of
disorders that patients whose health improved re-assessed
their former health state as worse than initially rated [5–
13]. Furthermore, in cancer patients the relative importance
of different domains of quality of life varied over time [14].
Finally, there are many studies that demonstrate that
patients value a certain health state differently than indi-
viduals not in that particular health state [7, 15–18], for
example that healthy people perceive the general health of
patients suffering from end-stage renal disease as worse
than the patients themselves [7].
In response shift theory, these ﬁndings are interpreted
[19] as follows: patients do not rate their own health in
reference to an absolute standard but in reference to a
relative standard. In health-related subjective measures,
this relative standard is tentatively taken as the patient’s
own current health state. However, current health, and
therefore an individual’s standard, may change over time
[19–21]. For example, when a patient is asked whether
or not he or she has improved, the fact that the patient
refers to his/her current health can lead to different
valuations of the same objective health state at different
moments in time. Some authors suggest that self-reported
outcomes should be corrected for changes in relative
standards [22, 23] by, for instance, a then-test [22]. By
using a then-test, patients are asked to re-rate a former
health state from their current perspective. Because the
former health state and the follow-up health state are
then rated from the same perspective, the change in
health (then-minus-post) is corrected for a possible
change in internal standards.
Support for the then-test as a correction for changes in
relative standards can be found in prospect theory [24, 25].
Prospect theory was originally developed in the context of
gambling for money and is a theory about decisions under
risk [26]. Prospect theory deﬁnes money outcomes as gains
and losses relative to a reference point. Different reference
frames are assumed to shift the reference point along the
outcome dimension, altering the location of an S-shaped
value function [25, 27]. In valuing health, the reference
point of the S-shaped value functions can be described as
the individual’s current health, as described by Treadwell
and Lenert [25]. Figure 1 shows two such S-shaped value
functions for two different health states in time, A and B.
The x-axis represents a person’s health state, and the y-axis
represents subjective values attributed to health states.
When a patient improves in health (moves from A to B),
his value function shifts to B. According to the shifted S-
shaped value function, the former state is rated worse (A’)
than previously (A). When a patient deteriorates in health
(moves from B to A), his value function shifts to the left.
According to that function, the former health state will
receive a better rating (B’) than previously (B). When a
health state remains stable, no shift in the value function is
expected. Prospect theory therefore provides a clear illus-
tration of the predictions of response shift theory with
respect to recalibration response shifts. Hence, this study
explores the predictions by prospect theory to explain
response shift.
However, it should be noted that alternative predictions
of outcomes of the then-test can be found in, for example,
Norman’s discussion of implicit theory of change [28].
This theory originates in psychological research [29] and
states that individuals might be unable to accurately
remember a former situation but instead extrapolate
backwards from their present state invoking an implicit
theory of change [28, 29]. A treatment received could
trigger an implicit theory of positive change. Working back
from their present health status, such an implicit positive
change would lead patients to re-rate their baseline health
status (then-test) as worse than their initial baseline rating
independent of the actual effectiveness of the treatment.
That patients re-rate (by means of a then-test) their
former health state as worse than previously after an
improvement in health has been shown several times in the
medical ﬁeld [5–13]. However, there is very little evidence
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123in the literature for predictions in patients who deteriorate
in health compared to patients who improve in health.
Response shift and prospect theory both predict that shifts
in internal standards will be bi-directional: retrospective
ratings of a former health state will be worse in patients
who improve (health state A’ worse than previously (A))
and better in patients who deteriorate (health state B’ rated
better than previously (B)). However, implicit theory of
change would predict that both patients who objectively
improve or deteriorate will rate their former health state as
worse than previously rated if patients perceive there
should have been an improvement.
The aim of this study was to explore the predictions
from response shift and prospect theory by relating sub-
jective change to objective change. This was done by
comparing retrospective scores in patients with severe and
prolonged rheumatoid arthritis who either deteriorated or
improved after treatment with TNF-blocking agents.
Methods
Study site and subjects
Our hypothesis was tested in a population of chronically ill
rheumatoid arthritis patients receiving anti-TNFa treat-
ment. This patient population was chosen, because of the
chronic character of the disease, which ensures the
possibility of adaptation by patients to their imperfect
health state, and thereby allows the reference level to shift.
Anti-TNFa is a promising treatment to establish a signiﬁ-
cant decrease in disease activity [30–32]. In addition, this
population was chosen because of the possibility of cate-
gorizing patients by disease activity based on a validated
objective measure of disease activity [33].
Data from a prospective registry were used. Since
February 2003, all rheumatoid arthritis patients, from 11
Dutch hospitals, who started on an anti-TNFa agent (either
adalimumab, etanercept or inﬂiximab) for the ﬁrst time,
were included in this registry [34]. The primary aim of this
registry is to evaluate and monitor anti-TNFa treatment in
rheumatoid arthritis patients. Since January 2004, then-
tests have been included in this registry.
Study design and outcome measures
Patients’ baseline characteristics were registered at the start
of the ﬁrst anti-TNFa treatment. These characteristics
included age, gender, weight, disease duration, rheumatic
factor status, the presence of one or more erosions in hand
or feet and number of previous DMARDs (disease modi-
fying anti-rheumatic drugs) used. In addition to these
characteristics, the three main measures for this study,
disease activity, the patient’s self-perceived general health
and self-perceived pain, were registered at baseline and at a
3-month follow-up assessment. The 3-month follow-up
Fig. 1 Two S-shaped value
functions for two different
health states in time. Modiﬁed
ﬁgure from the article by
Treadwell and Lenert [25].
Response shift: the difference
between A’-A or B’ and B.
Prospective change: difference
between A and B. Then-minus-
post change: difference between
A-B’ or B-A’
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123assessment was chosen because at that point a clinical
decision about the medication policy is made on the basis
of the underlying disease state alteration (with the
DAS28).
Disease activity was assessed using a modiﬁed Disease
Activity Score 28 (DAS28), which is a statistically
derived index combining the following variables: the 28
joint count for swelling (SW28), the 28 joint count for
tenderness (TEN28) and the Erythrocyte Sedimentation
Rate (ESR), with the ESR having the largest weight in the
algorithm [35]. In order to minimize subjective interpre-
tation of disease activity in our study, the VAS general
health was left out of the original DAS28 algorithm. As a
valid alternative to ESR, C-reactive Protein (CRP) scores
were used in case of missing ESR values [36]. The
research nurses were trained in giving a standardized
amount of pressure (deﬁned as causing whitening of the
examiners nail beds) on the joints to measure tenderness
and in using a standardized grip for assessing swelling
[36]. For the purpose of describing the population, we
also administered the disability index from the Health
Assessment Questionnaire (HAQ-DI). The HAQ-DI is a
self-assessed questionnaire asking about the ability of
patients to perform several daily activities over the past
week [37, 38]. The HAQ-DI is well validated and pro-
vides information on disease activity as well as joint
damage [39, 40]. The questionnaire provides a score
between zero and three, where a higher score indicates
more functional impairment.
The patients’ self-perceived general health and pain
were assessed on a 100-mm Visual Analogue Scale (VAS
GH and VAS pain), which are feasible, valid and reliable
methods to measure these constructs [1–3]. Patients were
asked to rate their health or pain by placing a vertical line
on a horizontal line, indicating the perceived amount of
health or pain. This line ranged from zero to one hundred,
where a score of zero indicates ‘‘worst imaginable general
health’’ or ‘‘extreme pain’’, and a score of one hundred
indicates ‘‘best imaginable general health’’ or ‘‘no pain’’,
respectively. Patients were asked to rate their current
general health at baseline and at 3 month follow-up. At
3 months, the patients were also asked to retrospectively
re-rate the baseline general health and pain by means of a
then-test [22, 41]. Patients were speciﬁcally instructed not
to try and remember what they scored at baseline (recall),
but to re-assess their health and pain at baseline from their
current perspective. We chose to use the then-test for
assessing response shift, because it is easy to use and it is
most frequently used by others in longitudinal studies [42].
The actual DAS28 and the response category were calcu-
lated in the dataset afterwards and were, therefore, not
known to the patient at the moment that he or she com-
pleted the scales and the then-test.
Statistical analysis
Descriptives of baseline characteristics were determined.
Baseline values were subtracted from then-test score. A
negative difference indicated that retrospective scores are
worse than baseline scores (Fig. 1: A’-A), and a positive
difference indicated that retrospective scores are better than
baseline score (Fig. 1: B’-B). Changes over time in VAS
scores were calculated as either prospective change or
then-minus-post change. The prospective change was cal-
culated by subtracting baseline scores from 3-month fol-
low-up scores (Fig. 1: difference between A and B). A
positive prospective change was interpreted as an
improvement in health and a negative prospective change
as deterioration in health. Post-minus-then change was
calculated by subtracting then-test scores from the 3-month
follow-up scores (Fig. 1: A-B’ or B-A’). One can consider
the post-minus-then change as a prospective change cor-
rected for a shift in internal standards (then-test score at
3 months referring to baseline). A positive post-minus-then
change suggests a perceived improvement and a negative
post-minus-then change suggests a perceived deterioration.
To test the hypothesis that patients who deteriorated
retrospectively rate a former health state as better and
patients who improved retrospectively rate a former have
state as worse, patients were divided into three groups
(non-responders, moderate responders and good responders
to treatment) depending on their objectively determined
European League Against Rheumatism (EULAR) response
status at the 3-month follow-up moment. The EULAR
criteria were used because these have shown good con-
struct, criterion and discriminant validity [43]. The EU-
LAR criteria are based on the modiﬁed DAS28 and
combine prospective change and absolute level of attained
disease activity (Table 1). By this deﬁnition, the non-
response group is a mixture of patients who do not improve
signiﬁcantly and patients who deteriorate. Additionally,
Table 1 EULAR response criteria (good, moderate, non-response)
Present DAS28 Change in DAS28
[1.2 [0.6
en B 1.2
B0.6
DAS28 B 3.2 (low) Good Moderate Non-
response
3.2\DAS28 B 5.1
(moderate)
Moderate Moderate Non-
response
DAS28[5.1 (high) Moderate Non-
response
Non-
response
Disease activity score 28 (DAS28) is a continuous score ranging from
0 to 10 in which 0 represents no disease activity and 10 present high
disease activity. Thresholds as used in this table are validated
thresholds for low, moderate or high disease activity [43]
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123patients who deteriorated signiﬁcantly, deﬁned as at least
one population standard deviation (0.6 DAS28) deteriora-
tion (negative prospective change), were analysed as a
subgroup.
Baseline characteristics were tested for equivalency
between the groups by means of Chi-square tests, inde-
pendent samples t-tests and Mann–Whitney U tests. The
mean difference between then-test scores and baseline
scores and the mean changes in VAS general health and
VAS pain were tested for statistical signiﬁcance using one-
sample t-tests and were compared between groups using
independent samples t-tests. All analyses were performed
using the statistical software package SPSS 14.0.2 (SPSS
Inc., Chicago, IL.)
Results
Between January 2004 and December 2006, 212 patients
had completed 3-month follow-up data. Fifteen patients
were excluded from the analysis due to missing DAS28
and/or VAS data. Baseline characteristics of excluded
patients did not differ from included patients. Thus, 197
patients remained eligible for the analyses: 51 (25.9%)
patients were classiﬁed as good responders to the anti-
TNFa therapy, 83 (42.1%) as moderate responders, and 63
patients (32.0%) were classiﬁed as non-responders to
therapy. In this last group, 11 patients deteriorated signif-
icantly and were analysed as a subgroup. On the DAS28,
responders had a mean improvement of 2.2 points (ranging
from 1.2 to 4.5), moderate responders had a mean
improvement of 1.5 points (ranging from 0.6 to 4.2), and
non-responders had no improvement (mean -0.05, ranging
from -3.0 to 1.1). Table 2 shows the baseline character-
istics of clinically responding and non-responding patients.
These data show that clinically classiﬁed responders did
not differ from non-responders at baseline, except on the
clinical outcome measures HAQ and DAS28. This was to
be expected, because the EULAR response criteria com-
bine change and an absolute level of attained DAS28 and,
thus, baseline DAS28. The HAQ is strongly correlated with
the DAS28.
Prospective change
Table 3 and the Figs. 2 and 3 show the changes in VAS
scores on both general health (Fig. 2, solid line) and pain
(Fig. 3,solidline).Onaverage,clinicalobjectiveresponders
(good and moderate) to therapy scored an average of 31.0
pointsimprovementontheVASgeneralhealth, whichwasa
statistically signiﬁcant improvement and a signiﬁcantly
bigger improvement than the average 9.3 points improve-
mentthatwasreportedbynon-responders.OntheVASpain,
good and moderate responders scored a signiﬁcant mean
improvement of 31.8 points and 30.9 points, respectively,
whereas non-responders reported an insigniﬁcant improve-
ment of 6.0 points. Patients who deteriorated according to
their modiﬁed DAS28 scores deteriorated also according to
Table 2 Baseline characteristics of patients grouped by response
classiﬁcation
Good
responder
N = 51
Moderate
responder
N = 83
Non-
responder
N = 63
P-value
Age 51.5 (13.0) 54.0 (12.5) 54.9 (15.7) 0.427
HAQ 1.2 (0.6) 1.5 (0.6) 1.3 (0.7) 0.032
DAS28 4.5 (0.9) 5.5 (0.9) 4.6 (1.3) \0.001
Disease
duration*
6.0 (11.8) 6.0 (11.0) 6.0 (8.0) 0.896
Number
of previous
DMARDs*
3.0 (2.0) 3 (2.0) 3.0 (2.0) 0.272
% female 71.4 78.3 62.9 0.126
% with Cone
erosion
76.6 61.7 63.3 0.202
% positive
rheumatoid
factor
70.8 77.1 71.0 0.626
Values are presented as mean (standard deviation) unless stated
otherwise. * median (interquartile range). Abbreviations: HAQ Health
assessment questionnaire; DAS28 disease activity score of 28 joints;
DMARD disease modifying anti-rheumatic drugs
Table 3 The prospective change (3 months minus baseline) and the response shift (then-test minus baseline value) for the VAS general health
(GH) and pain for responders and non-responders
Good responder (N = 51) Moderate responder (N = 83) Non-responder (N = 63) P-value between groups
Prospective change VAS GH 31.0 (22.7; 39.3) 31.0 (25.7; 36.2) 9.3 (2.5;16.1) \0.0001
Prospective change VAS Pain 31.8 (24.8; 38.8) 30.9 (24.9; 36.8) 6.0 (-0.4;12.4) \0.0001
Response shift VAS GH -9.7 (-16.2; -3.2) -3.3 (-7.1; 0.6) -6.8 (-12.6; -0.9) 0.219
Response shift VAS Pain -10.7 (-18.3; -3.2) -4.6 (-8.7; -0.5) -10.9 (-16.4; -5.5) 0.148
Values are presented as mean (95% CI)
* mean difference between responders and non-responders
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123theirVASGH(mean12.3points)andpainscores(mean17.7
points).
Retrospective scores
Objectively classiﬁed responders and non-responders
showed signiﬁcant worse retrospective scores compared to
baseline values on both scales (Figs. 2 and 3, dotted lines).
The identiﬁed difference between the retrospective scores
and the baseline scores were of equal size for responders
and non-responders (Table 3). The 11 deteriorated patients
showed a signiﬁcant difference between retrospective score
and baseline values on general health of -14.5 (95% CI -
28.3; -0.8) and on pain of -19.1 (95% CI -36.9; -1.3).
Then-minus-post scores
The calculated mean then-minus-post scores are also
shown in Figs. 2 and 3. When applying the then-minus-
post values, clinical good and moderate responders to
therapy averaged a 40.7-point and 34.2-point improvement
on VAS general health, respectively. This was statistically
signiﬁcant (P\0.0001) and signiﬁcantly more than the
average 16.1-point improvement of the non-responders
(P\0.0001). Outcomes of the VAS Pain showed similar
results. Good and moderate responders averaged a 42.6-
point and 35.2-point improvement, respectively, compared
to a signiﬁcantly lower (P\0.0001) improvement of 16.9-
points for non-responders. The deteriorated patients
showed stable disease activity when applying the then-
minus-post score for the VAS GH (mean 2.3 points) and
for the VAS pain (mean 1.4 points).
Discussion and conclusion
This study showed that both patients who improved
(responders) or stayed the same/deteriorated (non-
responders) rated their baseline health state worse than
actually rated at baseline, when asked 3 months later with a
then-test. Furthermore, paradoxical results occurred when
the then-test was applied (then-minus-post) for the purpose
of correcting for a shift in internal standards. For clinically
stable or deteriorating patients, an improvement in health
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Fig. 2 Changes in VAS general health scores and then-test values of
good responders (a), moderate responders (b), non-responders (c) and
deteriorators (d). Note that a score of zero indicates a worst
imaginable general health state, and a score of one hundred indicates
best imaginable general health
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123would be inferred when using then-minus-post ratings
when compared to using only prospective ratings (Figs. 2
and 3). The fact that patients who stayed the same or
deteriorated also reported worse health retrospectively
conﬂicted with the predictions from response shift theory
and prospect theory.
The negative response shifts in patients who improved
were in line with the predictions derived from prospect
theory and complied with the large amount of literature
reporting on negative response shifts [5–12]. However,
the negative response shifts in patients who stayed the
same or deteriorated, conﬂicted with the prediction from
prospect theory. Only two previous studies assessed
patients who improved, who did not improve or who
deteriorated in health. Results from one study were in line
with prospect theory [44], while ﬁndings from the second
study were not [5]. Ahmed and colleagues [5] also used
objective criteria to determine the direction of disease
change. In agreement with our study, they found mean
response shifts in the same direction in 196 participants.
These response shifts were independent of the direction of
the disease change that had occurred. Janssen et al. [44]
investigated response shift in 46 patients where the dis-
ease change was deﬁned with a subjective change ques-
tion. In contrast to Ahmed’s and our ﬁndings, their
response shifts were dependent on the direction of the
disease changes. The explanation for these conﬂicting
ﬁndings may be the crucial difference in the way that
disease change was deﬁned: objective (Ahmed’s and our
study) versus subjective (Janssen’s study).
The aforementioned implicit theory of change seems to
explain our results more accurately than prospect theory
and also the conﬂicting results in the literature. In our study
and the study by Ahmed et al. [5], non-responders showed
no objective disease change, but the treatment received
could have triggered an implicit positive change. Working
back from their health status, this implicit positive change
would lead patients to re-rate their baseline health status
A
V
A
S
 
p
a
i
n
0
20
40
60
80
100
Prospective rating
Then-test rating
C
V
A
S
 
p
a
i
n
0
20
40
60
80
100
Prospective rating
Then-test rating
Baseline health state 3-months health state
Baseline health state 3-months health state
B
V
A
S
 
p
a
i
n
0
20
40
60
80
100
Prospective rating
Then-test rating
Baseline health state 3-months health state
D
V
A
S
 
p
a
i
n
0
20
40
60
80
100
Prospective rating
Then-test rating
Baseline health state 3-months health state
Fig. 3 Changes in VAS Pain scores and then-test values of good responders (a), moderate responders (b), non-responders (c) and deteriorators
(d). Note that a score of zero indicates extreme pain, and a score of one hundred indicates no pain
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123(then-test) as worse than their initial baseline rating. In the
study by Jansen et al. [44], patients self-reported a sub-
jective deterioration in disease. Working back from their
health status, they could have applied this implicit negative
change to re-rate the baseline health status with the then-
test as better than their initial baseline rating. In summary,
an implicit positive change of patients in our and Ahmed’s
study and the implicit negative change of patients in
Janssen’s study can explain the conﬂicting retrospective
scores more accurately than response shift or prospect
theory. It has to be mentioned that an implicit positive
change as described above could also have resulted from
what is known as a placebo response, but either way
change results in patients re-rating their baseline health
status (then-test) as worse than their initial baseline rating.
The prediction of response shift theory, with respect to
the fact that the internal standards by which patients rate
their own health change over time, has clinical implica-
tions. This is especially true when subjective measures are
used to monitor therapy effectiveness as was recently
suggested in the ﬁeld of rheumatology [4]. It can be sug-
gested that physicians can try to correct for a shift in
internal standards by asking patients to rerate their health
state before they started therapy and rate their current
health. By comparing those two ratings, therapy effec-
tiveness can be evaluated. However, our results suggest
that rather than changing internal standards, implicit theory
of change is applied by patients to construct the value of a
former health state. Therefore, if retrospective ratings are
used, this will lead to the paradoxical result that patients
who deteriorate or stay the same increase signiﬁcantly on
self-reported health and pain. For a clinician, this would
make it more difﬁcult to justify treatment change where
from a more objective point of view or from the perspec-
tive of prospective self ratings, it would have been
advisable.
Lenert et al. [45] did empirical research in health care to
test predictions based on prospect theory. Patients from
primary care practices with various medical illnesses and
depression rated different hypothetical health states. They
showed data that were consistent with the predictions from
prospect theory: utility functions for health were ‘‘S’’
shaped and differed across levels of health [45]. The dif-
ferences between their study design (cross-sectional) and
our study design (longitudinal) may explain the differences
in results. Their subjects rated hypothetical health states
that were worse or better than their own health states, and
they did this during one session. In our study, the patients
had an actual change in their own health to either a worse
or a better health state, and then rerated their baseline
health with a then-test.
Another explanation for the fact that we did not conﬁrm
prospect theory may lie in the fact that the then-test may
not be the appropriate instrument to evaluate a former
health state and subsequently to measure response shift.
Although the then-test is most frequently used as an
instrument to measure response shifts [42], it has the lim-
itation that it can be subject to recall bias [23], and it is
dependent on the cognitive function of the subjects. Fur-
thermore, it has to be mentioned that the results of this
study apply to visual analogue scales, and the results
cannot be generalized to other quality of life measures like
the Short Form 36 (SF36) or EuroQol 5d (EQ5D) without
further research. It might be possible that prospect theory
ﬁts the predicted outcomes measured by the EQ-5D or SF-
36. On the other hand, response shifts as a result of changes
in internal standards may not occur in measures like the
SF36 or EQ5D, but response shift as a result of changes in
values or re-conceptualization may occur [19]. Currently,
there is no evidence that prospect theory predicts response
shift as a result of changing values or conceptualizations,
and it was not the focus of our study to deliver such
evidence.
Some shortcomings concerning this study have to be
mentioned. First, by using the EULAR criteria to deﬁne
disease change (Table 1), the non-response group was a
mixture of patients who did not improve signiﬁcantly
and patients who deteriorated. A subgroup of 11 patients
who deteriorated on the objective measure DAS28 was
analysed. These 11 deteriorated patients showed, con-
sistently with the other groups of patients, a signiﬁcant
negative response shift on general health and pain, rating
their baseline health state worse than initially rated. Such
a subgroup analysis might be underpowered. Further-
more, the DAS28 is used as an objective measure, whilst
it can be subject to interpretation especially in the
components ‘joint pain’ and ‘joint swelling’. To mini-
mize subjective interpretation in these components, all
research nurses were trained twice per year for per-
forming joint counts. Moreover, a modiﬁed DAS28 was
calculated using the most objective components, the ESR
and the joint counts, of which the ESR has the larger
weight in the combined score. Another limitation is that
the patients’ memory or perceptions of change were not
assessed, and therefore the implicit perception of change
could not be assessed.
In conclusion, the similar direction and magnitude of
retrospective ratings in objectively deﬁned improved and
non-improved patients suggests that patients do not nec-
essarily change their standards in line with their disease
change. If a then-test is used to correct for shifts in internal
standards, it might lead to the paradoxical result that
patients who do not improve or even deteriorate increase
signiﬁcantly on self-reported health and pain making it
more difﬁcult for the clinician to justify treatment change.
An alternative explanation for differences in retrospective
992 Qual Life Res (2010) 19:985–994
123and prospective ratings of health is the implicit theory of
change which is more successful in explaining our results
than prospect theory.
Acknowledgments We are indebted to all research nurses and
rheumatologist of the 11 departments of rheumatology for their par-
ticipation and contribution in the data collection of the DREAM
study. UMC ST Radboud, Nijmegen: J. Alberts, P. Barrera Rico, K.
Bevers, A. Branten, M. Creemers, J. Deenen, A. van Ede, T. van
Gaalen, E. de Groot, H. van Heereveld, F. van den Hoogen, R. Laan,
P.van Riel, L. Schalkwijk, M. Veerkamp, C. Versteegden, C. Vogel,
M. Vonk; Sint Maartens Kliniek, Nijmegen: H. Cats, A. Eijsbouts, M.
Franssen, I. Geerdink, S. Herfkens, F van den Hoogen, M. Jeurissen,
P. Koelmans, P. van ‘t Pad Bosch, D. de Rooij, A. Stenger, H. van
Wijk; Rijnstate Ziekenhuis Arnhem: T. Berends, C. Bijkerk, C. De
Gendt, J.Harbers, M. Janssen, A de Jong, H. Knaapen, H. Visser;
Medisch Spectrum Twente, Enschede: A. ter Avest, K. Drossaers, M.
Hoekstra, M. Kruijssen, I. Kuper, M. van de Laar, A. Mooij, H.
Vonkeman; Twenteborg Ziekenhuis Almelo: H. Bernelot Moens, E.
Bos, K. Drossaers, C. Haagsma, K. van de Hoeven, J. Oostveen;
Streekziekenhuis Midden Twente, Hengelo: H. Bernelot Moens, M.
Kleine Schaar; Medisch Centrum Leeuwarden, Leeuwarden: G. A. W.
Bruyn, E. N. Griep, M. Horbeek, P. M. Houtman, T. L. Jansen, K.
Rasing, A. Spoorenberg, A. Krol; Twee Steden Ziekenhuis, Tilburg:
R. van Berkel, H. Brus, E. van Gorp, W. Hissink Muller, A. van Roy,
M. Wijnands; Streekziekenhuis Zevenaar, Zevenaar: C. De Gendt, H.
Visser, P. Brakenhoff. Furthermore, we would like to acknowledge
Thea van Gaalen, Lia Schalkwijk and Carien Versteegden for the data
processing and Hans Groenewoud for the assistance in managing the
database. There was no ﬁnancial funding for this study, and conse-
quentlycomplete independence in designing the study, interpreting the
data, writing, and publishing the report.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Badia, X., Monserrat, S., Roset, M., & Herdman, M. (1999).
Feasibility, validity and test-retest reliability of scaling methods
for health states: The visual analogue scale and the time trade-off.
Quality of Life Research, 8, 303–310.
2. Dworkin, R. H., Turk, D. C., Revicki, D. A., Harding, G., Coyne,
K. S., Peirce-Sandner, S., et al. (2009). Development and initial
validation of an expanded and revised version of the Short-form
McGill Pain Questionnaire (SF-MPQ-2). Pain, 144, 35–42.
3. Green, C., Brazier, J., & Deverill, M. (2000). Valuing health-
related quality of life. A review of health state valuation tech-
niques. Pharmacoeconomics, 17, 151–165.
4. Pincus, T., Yazici, Y., Bergman, M., Maclean, R., & Harrington,
T. (2007). A proposed continuous quality improvement approach
to assessment and management of patients with rheumatoid
arthritis without formal joint counts, based on quantitative routine
assessment of patient index data (RAPID) scores on a multidi-
mensional health assessment questionnaire (MDHAQ). Best
Practice & Research. Clinical Rheumatology, 21, 789–804.
5. Ahmed, S., Mayo, N. E., Wood-Dauphinee, S., Hanley, J. A., &
Cohen, S. R. (2004). Response shift inﬂuenced estimates of
change in health-related quality of life poststroke. Journal of
Clinical Epidemiology, 57, 561–570.
6. Nieuwkerk, P. T., Tollenaar, M. S., Oort, F. J., & Sprangers, M.
A. (2007). Are retrospective measures of change in quality of life
more valid than prospective measures? Medical Care, 45, 199–
205.
7. Postulart, D., & Adang, E. M. (2000). Response shift and adap-
tation in chronically ill patients. Medical Decision Making, 20,
186–193.
8. Razmjou, H., Yee, A., Ford, M., & Finkelstein, J. A. (2006).
Response shift in outcome assessment in patients undergoing
total knee arthroplasty. Journal of Bone and Joint Surgery.
American Volume, 88, 2590–2595.
9. Rees, J., Clarke, M. G., Waldron, D., O’Boyle, C., Ewings, P., &
MacDonagh, R. P. (2005). The measurement of response shift in
patients with advanced prostate cancer and their partners. Health
Quality Life Outcomes, 3, 21.
10. Rees, J., Waldron, D., O’Boyle, C., Ewings, P., & MacDonagh,
R. (2003). Prospective vs retrospective assessment of lower uri-
nary tract symptoms in patients with advanced prostate cancer:
The effect of ‘response shift’. BJU International, 92, 703–706.
11. Ring, L., Hofer, S., Heuston, F., Harris, D., & O’Boyle, C. A.
(2005). Response shift masks the treatment impact on patient
reported outcomes (PROs): The example of individual quality of
life in edentulous patients. Health Quality Life Outcomes, 3, 55.
12. Smith, D. M., Sherriff, R. L., Damschroder, L., Loewenstein, G.,
& Ubel, P. A. (2006). Misremembering colostomies? Former
patients give lower utility ratings than do current patients. Health
Psychology, 25, 688–695.
13. ten Klooster, P. M., Drossaers-Bakker, K. W., Taal, E., & van de
Laar, M. A. F. J. (2006). Patient-perceived satisfactory
improvement (PPSI): Interpreting meaningful change in pain
from the patient’s perspective. Pain, 121, 151–157.
14. Visser, M. R., Oort, F. J., & Sprangers, M. A. (2005). Methods to
detect response shift in quality of life data: a convergent validity
study. Quality of Life Research, 14, 629–639.
15. Sackett, D. L., & Torrance, G. W. (1978). The utility of different
health states as perceived by the general public. Journal of
Chronic Diseases, 31, 697–704.
16. Boyd, N. F., Sutherland, H. J., Heasman, K. Z., Tritchler, D. L., &
Cummings, B. J. (1990). Whose utilities for decision analysis?
Medical Decision Making, 10, 58–67.
17. Dolan, P. (1996). The effect of experience of illness on health
state valuations. Journal of Clinical Epidemiology, 49, 551–564.
18. De Wit, G. A., Busschbach, J. J. V., & De Charro, F. T. (2000).
Sensitivity and perspective in the valuation of health status:
Whose values count? Health Economics, 9, 109–126.
19. Sprangers, M. A., & Schwartz, C. E. (1999). Integrating response
shift into health-related quality of life research: A theoretical
model. Social Science and Medicine, 48, 1507–1515.
20. Allison, P. J., Locker, D., & Feine, J. S. (1997). Quality of life: A
dynamic construct. Social Science and Medicine, 45, 221–230.
21. Adang, E. M. (2001). A comment on ‘‘response shift and adap-
tation in chronically ill patients’’ by Postulart and Adang. Med-
ical Decision Making, 21, 423–424.
22. Schwartz, C. E., & Sprangers, M. A. (1999). Methodological
approaches for assessing response shift in longitudinal health-
related quality-of-life research. Social Science and Medicine, 48,
1531–1548.
23. Schwartz, C. E., Sprangers, M. A. G., Carey, A., & Reed, G.
(2004). Exploring response shift in longitudinal data. Psychology
and Health, 19, 51–69.
24. Tversky, A., & Kahneman, D. (1981). The framing of decisions
and the psychology of choice. Science, 211, 453–458.
25. Treadwell, J. R., & Lenert, L. A. (1999). Health values and
prospect theory. Medical Decision Making, 19, 344–352.
26. Kahneman, D., & Tversky, A. (1979). Prospect theory—analysis
of decision under risk. Econometrica, 47, 263–291.
Qual Life Res (2010) 19:985–994 993
12327. Stalmeier, P. F. M., & Bezembinder, T. G. G. (1999). The dis-
crepancy between risky and riskless utilities: A matter of fram-
ing? Medical Decision Making, 19, 435–447.
28. Norman, G. (2003). Hi! How are you? Response shift, implicit
theories and differing epistemologies. Quality of Life Research,
12, 239–249.
29. Ross, M. (1989). Relation of implicit theories to the construction
of personal histories. Psychological Review, 96, 341–357.
30. Blumenauer, B., Judd, M., Cranney, A., Burls, A., Coyle, D.,
Hochberg, M., Tugwell, P., & Wells, G. (2003). Etanercept for
the treatment of rheumatoid arthritis. Cochrane Database System
Review, CD004525.
31. Navarro-Sarabia, F., riza-Ariza, R., Hernandez-Cruz, B., & Vi-
llanueva, I. (2006). Adalimumab for treating rheumatoid arthritis.
Journal of Rheumatology, 33, 1075–1081.
32. Blumenauer, B., Judd, M., Wells, G., Burls, A., Cranney, A.,
Hochberg, M., & Tugwell, P. (2002) Inﬂiximab for the treatment
of rheumatoid arthritis. Cochrane Database System Review,
CD003785.
33. van Gestel, A. M., Anderson, J. J., van Riel, P. L., Boers, M.,
Haagsma, C. J., Rich, B., et al. (1999). ACR and EULAR
improvement criteria have comparable validity in rheumatoid
arthritis trials. American College of Rheumatology European
League of Associations for Rheumatology. The Journal of
Rheumatology, 26, 705–711.
34. Kievit, W., Fransen, J., Oerlemans, A. J., Kuper, H. H., van der
Laar, M. A., de Rooij, D. J., et al. (2007). The efﬁcacy of anti-
TNF in rheumatoid arthritis, a comparison between randomised
controlled trials and clinical practice. Annals of the Rheumatic
Diseases, 66, 1473–1478.
35. Prevoo, M. L. L., VantHof, M. A., Kuper, H. H., Vanleeuwen, M.
A., VandePutte, L. B. A., & Vanriel, P. L. C. M. (1995). Modiﬁed
Disease-Activity Scores That Include 28-Joint Counts - Devel-
opment and Validation in A Prospective Longitudinal-Study of
Patients with Rheumatoid-Arthritis. Arthritis and Rheumatism,
38, 44–48.
36. Van Riel, P. L. C. M., Fransen, J., & Scott, D. L. (2004) EULAR
handbook of clinical assessments in rheumatoid arthritis. Alphen
aan de Rijn, The Netherlands: Van Zuiden Communications B.V.
37. Fries, J. F., Spitz, P. W., & Young, D. Y. (1982). The dimensions
of health outcomes—the health assessment questionnaire, dis-
ability and pain scales. Journal of Rheumatology, 9, 789–793.
38. Zandbelt, M. M., Welsing, P. M. J., van Gestel, A. M., & Van
Riel, P. L. C. M. (2001). Health assessment questionnaire mod-
iﬁcations: Is standardisation needed? Annals of the Rheumatic
Diseases, 60, 841–845.
39. Marra, C. A., Woolcott, J. C., Kopec, J. A., Shojania, K., Offer, R.,
Brazier, J. E., et al. (2005). A comparison of generic, indirect
utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and
disease-speciﬁc instruments (the RAQoL and the HAQ) in rheu-
matoid arthritis. Social Science and Medicine, 60, 1571–1582.
40. Russell, A. S., Conner-Spady, B., Mintz, A., Mallon, C., &
Maksymowych,W.P.(2003).Theresponsivenessofgenerichealth
status measures as assessed in patients with rheumatoid arthritis
receiving inﬂiximab. Journal of Rheumatology, 30, 941–947.
41. Howard, G. S., Schmeck, R. R., & Bray, J. H. (1979). Internal
invalidity in studies employing self-report instruments: A sug-
gestedremedy.JournalofEducationalMeasurement,16,129–135.
42. Schwartz, C. E., Bode, R., Repucci, N., Becker, J., Sprangers, M.
A., & Fayers, P. M. (2006). The clinical signiﬁcance of adapta-
tion to changing health: A meta-analysis of response shift.
Quality of Life Research, 15, 1533–1550.
43. van Gestel, A. M., Prevoo, M. L., ‘t Hof, M. A., van Rijswijk, M.
H., van de Putte, L. B., & van Riel, P. L. (1996). Development
and validation of the European league against rheumatism
response criteria for rheumatoid arthritis. Comparison with the
preliminary American college of rheumatology and the World
Health Organization/International league against Rheumatism
criteria. Arthritis and Rheumatism, 39, 34–40.
44. Jansen, S. J., Stiggelbout, A. M., Nooij, M. A., Noordijk, E. M.,
& Kievit, J. (2000). Response shift in quality of life measurement
in early-stage breast cancer patients undergoing radiotherapy.
Quality of Life Research, 9, 603–615.
45. Lenert, L. A., Treadwell, J. R., & Schwartz, C. E. (1999).
Associations between health status and utilities implications for
policy. Medical Care, 37, 479–489.
994 Qual Life Res (2010) 19:985–994
123